Global Dry Eye Drugs Revenue Is Nearly 37 Billion USD In 2017
Wednesday, 31 Oct, 2018
In the last several years, global market of Dry Eye Drugs developed rapidly, with an average growth rate of 11.84% during 2013 to 2017. In 2017, global revenue of Dry Eye Drugs is nearly 37 Billion USD; the actual sales are about 390 Million Unit.

The global average price of Dry Eye Drugs is in the increasing trend, from 8.48 USD/Unit in 2013 to 9.49 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.

The classification of Dry Eye Drugs includes Artificial?Tears, Anti-inflammatory?drugs and other, and the proportion of Artificial?Tears in 2017 is about 89%.

Dry Eye Drugs is widely used in Hospital, Drug?Stores and Online?Pharmacies?. The most proportion of Dry Eye Drugs is used in hospitals, and proportion is about 42%.

North America is the largest consumption place, with a consumption market share nearly 40% in 2017. Following North America, Asia Pacific is the second largest consumption place with the consumption market share of 25%. 

Market competition is intense. Allergan, Novartis AG, Valeant Pharmaceuticals, Santen Pharma, Shire, Johnson & Johnson, United Laboratories, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.